APPLICATION
ANDA211097
TYPE
ANDA
ORIGINAL APPROVAL
2023-11-16
LATEST ACTION
2024-11-07
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
TERIPARATIDEPrescription
TERIPARATIDE 0.56MG/2.24ML (0.25MG/ML) · SOLUTION · SUBCUTANEOUS
Approval history
2024-11-07Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.